search

Active clinical trials for "Depressive Disorder"

Results 2011-2020 of 5015

A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression...

Bipolar Depression

The specific aim of this study is to obtain preliminary evidence of the acute effectiveness and tolerability of aripiprazole in the treatment of bipolar depression.

Completed2 enrollment criteria

Biological Markers of Response to Treatment in Major Depressive Disorder

Major Depressive Disorder

The purpose of this study is to find out if two tests are useful in predicting whether someone with depression will get better when he or she is treated with an FDA approved antidepressant medication (either citalopram or escitalopram).

Completed8 enrollment criteria

An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice...

Depressive Disorder

The purpose of the study is to evaluate the efficacy of SSR149415 in the treatment of Major Depressive Disorder, defined as a change from baseline to visit 7 in the Hamilton Depression Rating Scale. To evaluate the tolerability, safety and efficacy on disability and quality of life in patients with major depressive disorder.To evaluate plasma concentrations of SSR149415.

Completed8 enrollment criteria

Study of Home-Based Exercise to Alleviate Postpartum Depression

Postpartum Depression

The purpose of this study is to evaluate the effectiveness of an aerobic home-based exercise program for the treatment of postpartum depression.

Completed6 enrollment criteria

A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder...

Depressive DisorderMajor Depression

The purpose of the study is to assess whether treatment with SR58611A can prevent relapse of depressive symptoms in patients with major depressive disorder. Relapse will be assessed using the MADRS scale.Patients who demonstrate improvement in depressive symptoms at the end of the initial 12-week open-label treatment period with SR58611A are randomized to continue SR58611A or switch to placebo under double blind conditions for up to 52 weeks of additional treatment. The secondary objective is to evaluate the safety of SR58611A in patients with MDD.

Completed10 enrollment criteria

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder...

Major Depressive Disorder

To evaluate the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR) in the treatment of Major Depressive Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Completed5 enrollment criteria

PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In...

Depressive Disorder and Anxiety Disorders

This six-arm study is being conducted to measure the effect of a combination of paroxetine and vestipitant on the arousal induced by public speaking in Seasonal Effective Disorder (SAD) patients, using functional brain imaging readouts (i.e., WAT(Wave Analysis Technology) PET(Positron Emission Tomography)), after one or eight weeks of treatment. The effect of paroxetine alone after one or eight weeks of treatment will also be measured.

Completed8 enrollment criteria

Problem-Solving Therapy for People With Major Depression and Chronic Obstructive Pulmonary Disease...

Pulmonary DiseaseChronic Obstructive1 more

This study will evaluate the effectiveness of problem-solving therapy combined with treatment adherence procedures in treating older people with major depression and chronic obstructive pulmonary disease.

Completed13 enrollment criteria

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.

Completed3 enrollment criteria

Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression

Depressive DisorderDepression

The purpose of this study is to examine the effectiveness of ethyl-eicosapentanoic acid (ethyl-EPA), an omega-3 fatty acid, in treating depression.

Completed4 enrollment criteria
1...201202203...502

Need Help? Contact our team!


We'll reach out to this number within 24 hrs